PharmaJet Brings Needle-Free Vaccine Tech to Egypt's Immunization Plan

PharmaJet has signed a strategic Memorandum of Understanding with Egypt’s Unified Procurement Authority (UPA) and leading pharmaceutical company EVA Pharma to enable introduction of needle-free vaccine delivery as part of their routine immunization program.

 The MoU was signed during Africa Health ExCon, held in Cairo, and focuses on deploying PharmaJet’s Tropis intradermal system, initially targeting inactivated polio vaccine (IPV) delivery.

This partnership aims to revolutionize the immunization market by providing painless, rapid delivery through needle-free inoculation, more than halving adverse events and increasing public acceptance. It is estimated this needle-free delivery system will decrease vaccination costs 38% over 6 years, a significant breakthrough for large-scale health programs.

Also Read: Needle-Free Injection System: A Game Changer in Less Pain Vaccination

The MoU describes localized manufacturing plans, and technology transfer, for sustainable distribution, and identify vaccine development across the other areas of vaccines, transforming Egypt into a regional hub for modern vaccinations. Furthermore, the MoU aligns and supports the Egyptian government’s Universal Health Insurance goals, and the child health program “1,000 Golden Days” initiative.

UPA is leading the national implementation, while EVA Pharma is leading the commercialization of the program, further establishing Egypt’s vision for innovative health improvements across Africa and the MENA region. PharmaJet’s entry signals a strong move toward sustainable, scalable immunization models that reduce dependency on traditional injection methods.